Publikationen, an denen er mitarbeitet ANA MARIA PILAR GONZALEZ RODRIGUEZ (23)

2023

  1. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia

    Cancer Immunology, Immunotherapy, Vol. 72, Núm. 7, pp. 2529-2539

  2. Chemo-Immunotherapy: A New Trend in Cancer Treatment

    Cancers, Vol. 15, Núm. 11

2021

  1. Btla/hvem axis induces nk cell immunosuppression and poor outcome in chronic lymphocytic leukemia

    Cancers, Vol. 13, Núm. 8

  2. Checkpoint inhibition in the fight against cancer: NK cells have some to say in it

    Successes and Challenges of NK Immunotherapy: Breaking Tolerance to Cancer Resistance (Elsevier), pp. 267-304

  3. Lag‐3 blockade with relatlimab (Bms‐986016) restores anti‐leukemic responses in chronic lymphocytic leukemia

    Cancers, Vol. 13, Núm. 9

2020

  1. Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT

    Bone Marrow Transplantation

  2. Driver mutations and single copy number abnormalities identify binet stage a patients with chronic lymphocytic leukemia with aggressive progression

    Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-8

2019

  1. NK cell-based immunotherapy in cancer metastasis

    Cancers, Vol. 11, Núm. 1

  2. NK cells in the treatment of hematological malignancies

    Journal of Clinical Medicine, Vol. 8, Núm. 10

  3. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling

    Frontiers in Immunology, Vol. 10

2018

  1. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia

    Frontiers in immunology, Vol. 9, pp. 2917

2017

  1. Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia

    OncoImmunology, Vol. 6, Núm. 10

2016

  1. Analysis of clinical prognostic variables for Chronic Lymphocytic Leukemia decision-making problems

    Journal of Biomedical Informatics, Vol. 60, pp. 342-351

2015

  1. On the prediction of Hodgkin lymphoma treatment response

    Clinical and Translational Oncology, Vol. 17, Núm. 8, pp. 612-619

2014

  1. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia.Correlation with progressive disease

    PLoS ONE, Vol. 9, Núm. 10

  2. Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells

    BioMed Research International, Vol. 2014

  3. Molecular bases for the regulation of NKG2D ligands in cancer

    Frontiers in Immunology

2013

  1. Lenalidomide and chronic lymphocytic leukemia

    BioMed Research International, Vol. 2013

2012

  1. Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: Association with soluble MICA shedding

    Cancer Immunology, Immunotherapy, Vol. 61, Núm. 8, pp. 1201-1210

2011

  1. Conceptual aspects of self and nonself discrimination

    Self/Nonself - Immune Recognition and Signaling, Vol. 2, Núm. 1, pp. 19-25